Breast cancer is a cause of death in women, making it a significant issue in women's health. The aim of this study was to evaluate the effects of nanoparticles (NPs) of FeONPs@pectin and FeONPs@SiO on MCF-7 cells. FeONPs@pectin and FeONPs@SiO NPs were prepared using the chemical coprecipitation technique. The characteristics of the NPs were determined using physical methods. The cytotoxic effects of the NPs were assessed by the MTT assay. The expression levels of BAX, BCL2, and TPX1 genes were determined using real-time PCR. The results indicated a density ratio of 0.11, a saturation magnetism value of 68.5 emu/g, and a spherical with sizes of 98 nm for the NPs. The MTT assay showed that 500 μg/mL of NPs had 75 % toxicity on MCF-7 cells after five days. The increased expression of BAX with 250 μg/mL of FeO@pectin showed a significant relationship (p-value = 0.0030). Down-regulated expression of BCL2 showed a significant relationship between the three groups treated with 250 μg/mL and 500 μg/mL of FeO@SiO and 250 μg/mL of FeO@pectin (p-values of 0.0014, 0.0009 and 0.0030, respectively). Additionally, decreased TPX indicated a significant relationship between treatment at 125, 250 and 500 μg/mL of FeO@SiO (p-values of 0.0388, 0.0063 and 0.0496, respectively).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2024.137082DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
expression bax
8
feonps@pectin feonps@sio
8
mcf-7 cells
8
mtt assay
8
250 μg/ml feo@pectin
8
500 μg/ml feo@sio
8
nps
6
effects feonps@sio2
4
feonps@sio2 feonps@pectin
4

Similar Publications

Background: Primary luminal breast cancer cells lose their identity rapidly in standard tissue culture, which is problematic for testing hormone interventions and molecular pathways specific to the luminal subtype. Breast cancer organoids are thought to retain tumor characteristics better, but long-term viability of luminal-subtype cases is a persistent challenge. Our goal was to adapt short-term organoids of luminal breast cancer for parallel testing of genetic and pharmacologic perturbations.

View Article and Find Full Text PDF

Background: Triple negative breast cancer (TNBC) belongs to the worst prognosis of breast cancer subtype probably because of distant metastasis to other organs, e.g. lungs.

View Article and Find Full Text PDF

Tumor microenvironment and immunotherapy for triple-negative breast cancer.

Biomark Res

December 2024

Department of Surgical Oncology, Affiliated Sir Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, 310016, Zhejiang, China.

Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans.

View Article and Find Full Text PDF

Introduction: Breast cancer is the leading cause of cancer amongst women in the United Kingdom, with implant-based reconstruction (IBR) using Acellular Dermal Matrices (ADM) gaining popularity for post-mastectomy procedures. This study compares outcomes of different ADMs that are commonly used in women undergoing IBR, this was short and long-term complications.

Methods: A systematic search of MEDLINE, Embase, CENTRAL, and CDSR databases was performed according to the PRISMA guidelines, focusing on women undergoing IBR with FlexHD, AlloDerm, Bovine, or Porcine ADMs.

View Article and Find Full Text PDF

Over the past few decades, microtubules have been targeted by various anticancer drugs, including paclitaxel and eribulin. Despite their promising effects, the development of drug resistance remains a challenge. We aimed to define a novel cell death mechanism that targets microtubules using eribulin and to assess its potential in overcoming eribulin resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!